A Randomized, Double-Blind, Placebo Controlled, Multicenter Phase 2a Study to Assess Safety, Daily Respiratory Symptoms, Pharmacokinetics, and Biomarker Variations After Administration of Either YPL-001, or Placebo in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
Phase of Trial: Phase II
Latest Information Update: 02 Dec 2016
At a glance
- Drugs YPL 001 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Proof of concept
- Sponsors Yungjin Pharm Co
- 07 Jun 2017 Biomarkers information updated
- 29 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Jul 2017.
- 29 Nov 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Feb 2017.